Trially secures $4.7M seed round, launches ‘Margo’ AI solution to clear patient bottleneck

A Kansas City startup’s AI-first platform is expected to save time — and patient lives — thanks to a successful seed round for its clinical trial recruitment tech, explained Kyle McAllister, noting his startup’s solution could help speed up access to treatment by years.

Trially, one of Startland News’ 10 Kansas City Startups to Watch in 2025, on Tuesday announced a $4.7 million funding round, led by led by Kansas City-based Flyover Capital, with participation from Alpaca, Atria, Blu Ventures, Looking Glass Capital, Redbud, The Council, and Gaingels.

“We’re bridging the gap between life-saving medicine and the people who need it now,” said McAllister, co-founder of Trially, which aims to get patients into clinical trials faster by using its artificial intelligence tools to immediately match and engage them with the right programs.

The simple concept: patients shouldn’t have to wait years for life-saving treatments while trials are running in their own backyard, McAllister added.

Another pain point: With 86 percent of clinical trials delayed because of recruitment failures, the pharmaceutical industry is losing more than $600,000 every day.

“Clinical trial recruitment has been the industry’s Achilles’ heel for decades,” said Thad Langford, founding partner at Flyover Capital. “Trially is the first solution we’ve seen that not only identifies eligible patients, but also engages and enrolls them. We’re thrilled to back Kyle and the Trially team as they accelerate access to life-saving treatments.”

ICYMI: Trially combines founders’ lived experiences, AI to streamline critical stage of health care advancements

Kyle McAllister, Ramon Prieto, and Trevor Welch, Trially; courtesy photo

The startup on Tuesday also officially announced “Margo,” its agentic AI solution that converts patient matches into participants with its trio of offerings:

• Trially Match — safely reads rich medical data to instantly match patients to trials 
• Trially Connect — Margo agentic AI outreach directly pre-screens patient matches to convert qualified candidates into enrollments. 
• Trially Intelligence — pipeline radar that proactively alerts a user to trials that are a fit for their patient population with instant feasibility analytics 

“Recruitment has always been the bottleneck in clinical research,” said McAllister. “With Margo, we’re not just matching patients, we’re engaging and enrolling them. That’s what sets Trially apart: we can identify patients with 95 percent screening accuracy and then agentic AI can engage them at the exact moment it matters most.”

Trially is the first fully integrated AI platform to tackle the root cause of delay, the company said. Its HIPAA-compliant LLM agents safely analyze unstructured medical data to instantly match, connect and enroll patients in relevant trials — transforming a process that once required 100s of hours of manual chart reviews and cold calling into instant enrollment opportunities.

With its new funding, Trially is expected to accelerate adoption of its platform across research sites, pharmaceutical sponsors, CROs and physician networks, ensuring sponsors can avoid costly delays and patients can access life-saving treatments when it matters most, McAllister said.

RELATED: Trially scaling to next level as an early investor forecasts unlocked opportunity